Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03114566 · ClinicalTrials.gov registry record

Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.

Terminated
Registry status
1
Enrollment target

NCT03114566: Clinical Trial study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03114566 is a clinical trial that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03114566 was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.

TERMINATED
Registry status
1 participants
Enrollment target

Study Summary

The purpose of this study is to obtain lymphocyte collections from normal healthy volunteer donors in order to create Good Manufacturing Practice grade banks of virus-specific and tumor-reactive T-cells of defined HLA type and restricting HLA allele readily available for therapeutic use.

Primary Outcome

Blood and/or white cell donations will be used for the generation of the T-cells to be used for adoptive immunotherapy.

Interventions

  • OTHER Leukapheresis

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2017-04-05
Est. Completion 2021-02-02
Memorial Sloan Kettering Cancer Center

1,884 total trials

Why NCT03114566 stopped before completion

NCT03114566 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Leukapheresis is the first listed.

NCT03114566 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03114566 about?

NCT03114566 is a clinical study titled "Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors". The purpose of this study is to obtain lymphocyte collections from normal healthy volunteer donors in order to create Good Manufacturing Practice grade banks of virus-specific and tumor-reactive T-cells of defined HLA type and restricting HLA allele readily available for therapeutic use.

What is the current status of trial NCT03114566?

This trial is currently terminated. The enrollment target is 1 participants. The study started on 2017-04-05. Estimated completion is 2021-02-02.

What interventions are being tested in trial NCT03114566?

The interventions under investigation include: Leukapheresis (OTHER).

Who is sponsoring clinical trial NCT03114566?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03114566, the US trial registry maintained by the National Library of Medicine. NCT03114566 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.